Publicaciones en colaboración con investigadores/as de Ottawa Hospital (6)

2023

  1. Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia

    Future Oncology, Vol. 19, Núm. 5, pp. 345-353

2022

  1. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 1, pp. 52-62

  2. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

    Blood, Vol. 140, Núm. 21, pp. 2248-2260

2021

  1. Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial

    Bone Marrow Transplantation, Vol. 56, Núm. 6, pp. 1413-1421

2018

  1. Phase 3 trial of Ibrutinib plus rituximab in Waldenstrom's macroglobulinemia

    New England Journal of Medicine, Vol. 378, Núm. 25, pp. 2399-2410

2016

  1. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma

    Biology of Blood and Marrow Transplantation, Vol. 22, Núm. 10, pp. 1808-1815